Generic Name: glucagon
Brand Name: Baqsimi
Manufacturer: Eli Lilly Canada Inc.
Indications: Severe hypoglycemic reactions
Manufacturer Requested Reimbursement Criteria1: For the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.
Submission Type: New
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient input posted | June 25, 2019 |
| Patient group input closed | August 15, 2019 |
| Clarification: - Patient input submission received from Diabetes Canada and Type 1 Together/Ensemble | |
| Patient input summary sent for review to patient input groups | September 12, 2019 |
| Patient group comments on input summary closed | September 19, 2019 |
| Clarification: - Patient input summary feedback received | |
| Submission received | July 24, 2019 |
| Submission accepted for review | August 08, 2019 |
| Review initiated | August 09, 2019 |
| Draft CADTH review report(s) sent to sponsor | October 24, 2019 |
| Comments from sponsor on draft CADTH review report(s) received | November 04, 2019 |
| CADTH review team's comments on draft CADTH review report(s) sent to sponsor | November 29, 2019 |
| Canadian Drug Expert Committee (CDEC) meeting | December 11, 2019 |
| CDEC recommendation sent to sponsor and drug plans | December 23, 2019 To January 02, 2020 |